Options exercised as ACM Research (NASDAQ: ACMR) insider sells 98,551 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ACM Research, Inc. officer Mark McKechnie exercised stock options and sold the resulting shares. He exercised options covering 98,551 shares of Class A common stock at exercise prices of $13.89 and $19.49 per share, then sold 98,551 shares in open-market transactions at weighted average prices in the mid-$40s. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 98,551 shares ($4,491,952)

Net Sell 10 txns

Insider McKechnie Mark

Role See Remarks

Sold 98,551 shs ($4.49M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	60,000	$0.00	--
Exercise	Stock Option	38,551	$0.00	--
Exercise	Class A Common Stock	60,000	$13.89	$833K
Sale	Class A Common Stock	11,910	$44.89	$535K
Sale	Class A Common Stock	47,108	$45.74	$2.15M
Sale	Class A Common Stock	982	$46.55	$46K
Exercise	Class A Common Stock	38,551	$19.49	$751K
Sale	Class A Common Stock	8,639	$44.94	$388K
Sale	Class A Common Stock	29,348	$45.74	$1.34M
Sale	Class A Common Stock	564	$46.57	$26K

Holdings After Transaction: Stock Option — 240,000 shares (Direct); Class A Common Stock — 60,900 shares (Direct)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.37 to $45.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), (4), (5), (6) and (7) to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.39 to $46.59, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.40 to $45.39, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.40 to $46.39, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.45 to $46.59, inclusive. The option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

03/13/2026 - 09:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKechnie Mark

(Last)

(First)

(Middle)

C/O ACM RESEARCH, INC.

42307 OSGOOD ROAD, SUITE I

(Street)

FREMONT

94539

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ACM Research, Inc. [ ACMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	03/12/2026		M		60,000	A	$13.89	60,900	D
Class A Common Stock	03/12/2026		S⁽¹⁾		11,910	D	$44.89⁽²⁾	48,990	D
Class A Common Stock	03/12/2026		S⁽¹⁾		47,108	D	$45.74⁽³⁾	1,882	D
Class A Common Stock	03/12/2026		S⁽¹⁾		982	D	$46.55⁽⁴⁾	900	D
Class A Common Stock	03/12/2026		M		38,551	A	$19.49	39,451	D
Class A Common Stock	03/12/2026		S⁽¹⁾		8,639	D	$44.94⁽⁵⁾	30,812	D
Class A Common Stock	03/12/2026		S⁽¹⁾		29,348	D	$45.74⁽⁶⁾	1,464	D
Class A Common Stock	03/12/2026		S⁽¹⁾		564	D	$46.57⁽⁷⁾	900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$13.89	03/12/2026		M			60,000	⁽⁸⁾	08/09/2033	Class A Common Stock	60,000	$0	240,000	D
Stock Option	$19.49	03/12/2026		M			38,551	⁽⁸⁾	08/11/2032	Class A Common Stock	38,551	$0	61,449	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.37 to $45.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), (4), (5), (6) and (7) to this Form 4.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.39 to $46.59, inclusive.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.40 to $45.39, inclusive.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.40 to $46.39, inclusive.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.45 to $46.59, inclusive.

8. The option is fully vested and exercisable.

Remarks:

Chief Financial Officer and Treasurer

	/s/ Mark McKechnie	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ACM Research (ACMR) insider Mark McKechnie do in this Form 4?

Mark McKechnie exercised stock options and sold the resulting shares. He exercised options for 98,551 ACM Research Class A shares, then sold 98,551 shares in open-market trades at weighted average prices in the mid-$40s.

How many ACM Research (ACMR) shares were sold in the reported transactions?

The filing reports open-market sales totaling 98,551 shares of ACM Research Class A common stock. These sales occurred across multiple trades at weighted average prices generally between about $44 and $47 per share, as detailed in the transaction data and footnotes.

Were the ACM Research (ACMR) insider sales under a Rule 10b5-1 trading plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted on August 27, 2025. Such plans pre-schedule trades, indicating these dispositions were planned in advance rather than opportunistic market-timing decisions by the insider.

What stock option exercises did the ACM Research (ACMR) insider report?

McKechnie exercised two stock option grants. One covered 60,000 shares at an exercise price of $13.89, and the other covered 38,551 shares at $19.49. Together, these exercises converted 98,551 option rights into ACM Research Class A common shares.

Does this ACM Research (ACMR) Form 4 show any remaining stock options?

The derivative summary in the data is empty, and the transactions show exercises of 98,551 option shares. This indicates the reported option positions tied to these grants were fully exercised, with no remaining derivative position for those particular options in this filing.